Bright Minds Biosciences (DRUG) Cash from Restructuring (2022 - 2026)
Bright Minds Biosciences (DRUG) posted Cash from Restructuring of -$19154.8 for Q1 2026, down 2.64% on a QoQ basis from -$18662.2 in Q4 2025, and down 211.59% year-over-year from $17165.1 in Q1 2025.
Bright Minds Biosciences (DRUG) Cash from Restructuring (2022 - 2026) Analysis & Trends
Bright Minds Biosciences' Cash from Restructuring history runs 5 years deep, the most recent figure standing at -$19154.8 for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Bright Minds Biosciences | 498.53 Mn | 498.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19,154.78 |
| Dec 31, 2025 | -18,662.17 |
| Jun 30, 2025 | -88,380.91 |
| Mar 31, 2025 | 17,165.05 |
| Dec 31, 2024 | 17,030.05 |
| Jun 30, 2024 | 16,053.65 |
| Mar 31, 2024 | 16,294.58 |
| Dec 31, 2023 | 16,128.20 |
| Jun 30, 2023 | 15,997.54 |
| Mar 31, 2023 | 15,896.07 |
| Dec 31, 2022 | 15,830.27 |